These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35490314)

  • 1. Interactions Between Meropenem and Renal Drug Transporters.
    Dong J; Liu Y; Li L; Ding Y; Qian J; Jiao Z
    Curr Drug Metab; 2022 Aug; 23(5):423-431. PubMed ID: 35490314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
    Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
    Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of organic anion transporter 3 in the renal excretion of biapenem and potential drug-drug interactions.
    Li W; Jiao Z; Liu Y; Yao J; Li G; Dong J
    Eur J Pharm Sci; 2021 Jul; 162():105814. PubMed ID: 33753216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins.
    Shen H; Yao M; Sinz M; Marathe P; Rodrigues AD; Zhu M
    Mol Pharm; 2019 Sep; 16(9):4065-4076. PubMed ID: 31335150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal Drug Transporters and Drug Interactions.
    Ivanyuk A; Livio F; Biollaz J; Buclin T
    Clin Pharmacokinet; 2017 Aug; 56(8):825-892. PubMed ID: 28210973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid.
    Ren G; Qin Z; Yang N; Chen H; Fu K; Lu C; Lu Y; Li N; Zhang Y; Chen X; Zhao D
    Chem Biol Interact; 2020 Jun; 324():109097. PubMed ID: 32305507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K).
    Kikuchi R; Lao Y; Bow DA; Chiou WJ; Andracki ME; Carr RA; Voorman RL; De Morais SM
    J Pharm Sci; 2013 Dec; 102(12):4426-32. PubMed ID: 24122511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib.
    McCormick A; Swaisland H
    Xenobiotica; 2017 Oct; 47(10):903-915. PubMed ID: 27684210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug-drug interactions.
    Tong Z; Yerramilli U; Surapaneni S; Kumar G
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):869-74. PubMed ID: 24627218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical assessment of drug-drug interaction of fb-PMT, a novel anti-cancer thyrointegrin αvβ3 antagonist.
    Fujioka K; Fekry MI; Rumsey JM; Steiner T; Thompson D; Mousa SA
    Clin Transl Sci; 2023 Jun; 16(6):987-1001. PubMed ID: 36967488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4.
    El-Sheikh AA; Greupink R; Wortelboer HM; van den Heuvel JJ; Schreurs M; Koenderink JB; Masereeuw R; Russel FG
    Transl Res; 2013 Dec; 162(6):398-409. PubMed ID: 24036158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
    Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1).
    Lai Y; Sampson KE; Balogh LM; Brayman TG; Cox SR; Adams WJ; Kumar V; Stevens JC
    J Pharmacol Exp Ther; 2010 Sep; 334(3):936-44. PubMed ID: 20519552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transporter-mediated Natural Product-Drug Interactions.
    Bi Y; Wang X; Ding H; He F; Han L; Zhang Y
    Planta Med; 2023 Feb; 89(2):119-133. PubMed ID: 35304735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential interactions of the β-lactam cloxacillin with human renal organic anion transporters (OATs).
    Lalanne S; Le Vée M; Lemaitre F; Le Corre P; Verdier MC; Fardel O
    Fundam Clin Pharmacol; 2020 Aug; 34(4):476-483. PubMed ID: 32100322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transporter-mediated drug-drug interactions.
    Müller F; Fromm MF
    Pharmacogenomics; 2011 Jul; 12(7):1017-37. PubMed ID: 21787191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-associated differences in transporter gene expression in kidneys of male rats.
    Xu YJ; Wang Y; Lu YF; Xu SF; Wu Q; Liu J
    Mol Med Rep; 2017 Jan; 15(1):474-482. PubMed ID: 27909713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of human drug transporter activities by succinate dehydrogenase inhibitors.
    Kerhoas M; Le Vée M; Carteret J; Jouan E; Tastet V; Bruyère A; Huc L; Fardel O
    Chemosphere; 2024 Jun; 358():142122. PubMed ID: 38663675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.
    Reznicek J; Ceckova M; Ptackova Z; Martinec O; Tupova L; Cerveny L; Staud F
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.